Veradermics R&D chief reports zero MANE holdings
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Veradermics, Inc (MANE) had an initial statement of beneficial ownership filed for David Hollander, who serves as Chief R&D Officer. The filing reports no transactions and no beneficial ownership positions in Veradermics securities as of the reporting date.
Key Figures
Net buy/sell shares: 0 shares
1 metrics
Net buy/sell shares
0 shares
Transaction summary for David Hollander on initial Form 3
Key Terms
Form 3, beneficial ownership, reporting person
3 terms
Form 3 regulatory
"The company submitted a <b>Form 3</b>, which is an initial statement"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership regulatory
"an initial statement of <b>beneficial ownership</b> for officers, directors"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"The insider is David Hollander, the <b>reporting person</b> on the Form 3"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the insider in Veradermics, Inc (MANE)'s latest Form 3 filing?
The insider is David Hollander, who is reported as the Chief R&D Officer of Veradermics, Inc. The Form 3 identifies him as an officer but not as a director or ten percent owner.
What type of filing did Veradermics, Inc (MANE) submit for David Hollander?
The company submitted a Form 3, which is an initial statement of beneficial ownership for officers, directors, or large shareholders when they first become insiders of Veradermics, Inc.
Does the Form 3 for MANE report any stock transactions by David Hollander?
No. The Form 3 reports no transactions by David Hollander. The transaction summary shows zero buys, zero sells, zero derivative exercises, and no other transaction activity.
Does the Form 3 show any beneficial ownership by David Hollander in MANE?
The Form 3 reports no beneficial ownership positions for David Hollander, with zero holding entries and no derivative positions listed in the filing data.
Is there any Rule 10b5-1 trading plan noted in the MANE Form 3?
No. The Form 3 data show the Rule 10b5-1 plan indicator as null, and there are no transactions or footnotes indicating that any pre-arranged trading plan applies.
AI-generated analysis. How Rhea-AI works. Not financial advice.